Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor-Reference-Cited by-同舟云学术

Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor

Published:2023-01-12 Issue:2 Volume:14 Page:199-210
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Mamai Ahmed¹,Chau Anh M.¹,Wilson Brian J.¹,Watson Iain D.¹,Joseph Babu B.¹,Subramanian Pandiaraju R.¹,Morshed Monzur M.¹,Morin Justin A.¹,Prakesch Michael A.¹,Lu Tianbao²^ORCID,Connolly Pete²,Kuntz Douglas A.³,Pomroy Neil C.³,Poda Gennady¹⁴,Nguyen Kong¹,Marcellus Richard¹,Strathdee Graig¹,Theriault Brigitte¹,Subramaniam Ratheesh¹,Mohammed Mohammed¹,Abibi Ayome¹,Chan Manuel¹,Winston Jeffrey¹,Kiyota Taira¹,Undzys Elijus¹,Aman Ahmed¹⁴^ORCID,Austin Nigel²,Du Jardin Marc²,Packman Kathryn²,Phillippar Ulrike⁵,Attar Riccardo²,Edwards James²,O’Meara Jeff¹,Uehling David E.¹,Al-awar Rima¹⁶⁷,Privé Gilbert G.³⁸⁹,Isaac Methvin B.¹^ORCID

Affiliation:

1. Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, OntarioM5G 0A3, Canada

2. Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania19477, United States

3. Princess Margaret Cancer Centre, Toronto, OntarioM5G 2C1, Canada

4. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, OntarioM5S 3M2, Canada

5. Janssen Research & Development, Turnhoutseweg 30, B-2340Beerse, Belgium

6. Department of Chemistry, University of Toronto, Toronto, OntarioM5S 3H6, Canada

7. Department of Pharmacology and Toxicology, University of Toronto, Toronto, OntarioM5S 1A8, Canada

8. Department of Medical Biophysics, University of Toronto, Toronto, OntarioM5G 1L7, Canada

9. Department of Biochemistry, University of Toronto, Toronto, OntarioM5S 1A8, Canada

Funder

Ministry of Research and Innovation

Ontario Institute for Cancer Research

Johnson and Johnson Research and Development team

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00502

Reference21 articles.

1. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach

2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

3. Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions: Figure 1.

4. Germinal centres: role in B-cell physiology and malignancy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3;International Journal of Molecular Sciences;2024-02-04

2. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones;Journal of Medicinal Chemistry;2023-04-07

3. Design and Synthesis of BCL6 BTB Inhibitor OICR12694;Synfacts;2023-03-17